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ABSTRACT
Objective Explore the impact of COVID-19 on patients 
on the waiting list for liver transplantation (LT) and on 
their post- LT course.
Design Data from consecutive adult LT candidates with 
COVID-19 were collected across Europe in a dedicated 
registry and were analysed.
Results From 21 February to 20 November 2020, 136 
adult cases with laboratory- confirmed SARS- CoV-2 
infection from 33 centres in 11 European countries 
were collected, with 113 having COVID-19. Thirty- seven 
(37/113, 32.7%) patients died after a median of 18 
(10–30) days, with respiratory failure being the major 
cause (33/37, 89.2%). The 60- day mortality risk did 
not significantly change between first (35.3%, 95% CI 
23.9% to 50.0%) and second (26.0%, 95% CI 16.2% 
to 40.2%) waves. Multivariable Cox regression analysis 
showed Laboratory Model for End- stage Liver Disease 
(Lab- MELD) score of ≥15 (Model for End- stage Liver 
Disease (MELD) score 15–19, HR 5.46, 95% CI 1.81 to 
16.50; MELD score≥20, HR 5.24, 95% CI 1.77 to 15.55) 
and dyspnoea on presentation (HR 3.89, 95% CI 2.02 
to 7.51) being the two negative independent factors for 
mortality. Twenty- six patients underwent an LT after a 
median time of 78.5 (IQR 44–102) days, and 25 (96%) 
were alive after a median follow- up of 118 days (IQR 
31–170).
Conclusions Increased mortality in LT candidates 
with COVID-19 (32.7%), reaching 45% in those with 
decompensated cirrhosis (DC) and Lab- MELD score 
of ≥15, was observed, with no significant difference 
between first and second waves of the pandemic. 
Respiratory failure was the major cause of death. The 
dismal prognosis of patients with DC supports the 
adoption of strict preventative measures and the urgent 
testing of vaccination efficacy in this population. Prior 
SARS- CoV-2 symptomatic infection did not affect early 
post- transplant survival (96%).
INTRODUCTION
Patients with cirrhosis are at increased risk of infec-
tions and associated complications due to cirrhosis- 
associated immune dysfunction,1–4 with bacterial 
infections being the most frequent trigger of acute 
decompensation (AD) and acute- on- chronic liver 
failure (ACLF).5 6 Existing evidence indicates the 
possibility that viral infections may cause AD and 
ACLF.7 Although data on the role of SARS- CoV-2 
are limited, SARS- CoV-2 is particularly feared for 
patients with decompensated cirrhosis (DC) on the 
waiting list (WL) for liver transplantation (LT), as 
ACLF may lead to early death if patients cannot 
be transplanted in due time.8 Furthermore, the 
impact of SARS- CoV-2 infection on patients being 
transplanted after recovering from SARS- CoV-2 
is relatively unknown. Thus, the European Liver 
and Intestine Association (ELITA) and the Euro-
pean Liver Transplant Registry (ELTR) called for a 
prospective registry aiming to address the following 
issues:
1. What is the mortality risk of COVID-19 in LT 
candidates and which are the determinants of 
death on clinical presentation?
2. How frequently does COVID-19 trigger ACLF, 
thus increasing the urgency for LT after recov-
ering from COVID-19? Conversely, how many 
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patients developed severe respiratory failure and were re-
moved from the WL?
3. What is the post- LT course of patients with pre- LT 
COVID-19?
4. Did clinical presentation and course of COVID-19 differ be-
tween the two waves of the pandemic?
METHODS
Study population
ELITA/ELTR COVID-19 registry was circulated in February 
2020 among 149 LT centres affiliated to ELTR and located in 30 
European countries. All centres reporting at least one case were 
provided with a database and instructions on how to record 
structured data. Thirty- three centres responded having observed 
SARS- CoV-2 infection in adult LT candidates from 21 February 
to 20 November 2020.
Inclusion criteria include adult patients listed for LT, patients 
presenting with symptoms consistent with SARS- CoV-2 infec-
tion and confirmation of SARS- CoV-2 infection by a positive 
result on a reverse- transcriptase PCR (RT- PCR) assay of a spec-
imen collected on a nasopharyngeal swab or on bronchoalveolar 
lavage.
Exclusion criteria include patients with RT- PCR- confirmed 
SARS- CoV-2 infection without symptoms.
Patient and public involvement
It was not appropriate or possible to involve patients or the 
public in the design, or conduct, or reporting, or dissemination 
plans of our research.
Data collection and definitions
Demographic and clinical data, including clinical symptoms or 
signs on presentation, laboratory and radiological results during 
COVID-19 management, administered antiviral therapies and 
antithrombotic prophylaxis were retrospectively collected. All 
laboratory tests and radiological assessments were performed on 
the discretion of the treating physician. Serum creatinine was 
converted to milligram per decilitre for analysis. Obesity was 
defined as a Body Mass Index of >30 kg/m2. Model for End- 
stage Liver Disease (MELD) score stands for pure Laboratory 
Model for End- stage Liver Disease (Lab- MELD) score without 
additional points. Dyspnoea at admission was considered when 
combined with O2 saturation below 95. AD was defined as 
including one or more among the following events: de novo 
or worsening ascites, new or worsening hepatic encephalop-
athy, bacterial infection and/or variceal haemorrhage. The EASL 
Chronic Liver Failure Consortium (CLIF- C) definitions were 
used to determine the presence of ACLF in patients with AD and 
to calculate the CLIF- C- OF score and the CLIF- C ACLF score.8 
The submitted files from each centre were manually reviewed to 
assess for data quality, completeness and inconsistencies. In addi-
tion, submitting clinicians were contacted and asked to provide 
corrections or data integration whenever needed.
Comparative analysis
To understand the relative impact of COVID-19 on survival of 
cirrhotic patients listed for LT, a comparison was made with a 
control group of 91 cirrhotic patients hospitalised in 2016–2020 
for AD triggered by bacterial infection. This control group was 
also used to evaluate the impact of COVID-19 on liver func-
tion deterioration related to ACLF development and associated 
mortality.
Regulatory approval
Data were collected in accordance with General Data Protec-
tion Regulation, the European Union legislation and the ELTR 
privacy policy.
Statistical analysis
Analysis was led by the Research Centre on Public Health, Univer-
sity of Milan- Bicocca, Monza, Italy. A descriptive analysis of the 
cohort was carried out on the overall population and following 
stratification of the population by site of management, at home, 
in general wards and in intensive care units (ICU). Categorical 
variables were summarised through percentages, and contin-
uous variables through median, first quartile and third quartile. 
Categorical variables were compared using the χ2 or Fisher’s 
exact test; continuous variables were compared using the Mann- 
Whitney U- test or the Kruskall- Wallis test, when appropriate. All 
tests were two- sided and used a significance level of 0.05.
Cumulative incidence curves for LT from WL were constructed 
considering death as a competing risk.9 The association between 
mortality and baseline clinically relevant characteristics of 
symptomatic patients were evaluated through univariate Cox 
proportional hazard models. All characteristics analysed in the 
univariate model were included in a stepwise selection process 
that identified the best multivariate model.
Significance of this study
What is already known on this subject?
 ► Many publications have explored the impact of COVID-19 on 
patients with chronic liver disease, but no study has focused 
on patients on the waitlist for liver transplantation (LT).
What are the new findings?
 ► LT candidates with COVID-19 were at high risk of early death 
(32.7%), reaching 49.2% in those with decompensated 
cirrhosis (DC) and Laboratory Model for End- stage Liver 
Disease (Lab- MELD) score of ≥15, which is triple the 
mortality risk observed in listed patients with comparable 
Lab- MELD scores without COVID-19.
 ► The evaluation of two simple variables, Model for End- stage 
Liver Disease (MELD) class of ≥15 or <15 and dyspnoea 
(present or absent), allowed a clear distinction between the 
individual mortality risks on clinical presentation.
 ► Respiratory failure frequently resulted in LT candidate 
ineligibility for LT and was the most frequent cause of death.
 ► During the two waves of the pandemic, clinical presentation, 
course and mortality risk of COVID-19 did not significantly 
change.
 ► Short- term survival after LT was 96%, and no cases of SARS- 
CoV-2 reinfection were observed to date.
How might it impact on clinical practice in the foreseeable 
future?
 ► LT candidates with DC should rigorously adopt all the usual 
measures to prevent SARS- CoV-2 infection and reinforced 
vaccination programmes should be implemented as the 
efficacy of standard vaccines is much lower than that 
reported in the registration studies.
 ► The evaluation of lab- MELD score and dyspnoea at clinical 
presentation will aid clinicians in their decision- making.
 ► LT in patients with prior COVID-19 is encouraged.
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To compare the effect of COVID-19 or bacterial infection on 
risk of death, Cox proportional hazard models were performed 
after adjusting for MELD or Child- Pugh, and age, sex, aetiology 
and diabetes mellitus.
A further analysis was conducted to compare the patient char-
acteristics and outcomes of LT candidates infected during the 
two waves of the pandemic. The end of the first wave (June 
2020) and the beginning of the second wave (July 2020) were 
identified analysing the graphical trend in the number of new 
patients with COVID-19 reported in the registry. Overall 
survival of all patients was also provided. All statistical analyses 
were conducted using SAS V.9.4 and R V.4.0.0 (R Core Team, 
Vienna, Austria). The map was drawn using QGIS software 
V.3.10 (QGIS Development Team).
RESULTS
LT candidates with SARS-CoV-2 infection: patient disposition
Thirty- three centres from 11 European countries observed at 
least one LT candidate with RT- PCR- confirmed SARS- CoV-2 
infection. Of the 1865 patients on the WL at the participating 
sites, 136 LT candidates with SARS- CoV-2 infection (7.29%) 
were consecutively reported in the registry. Twenty- three 
(16.9%) were asymptomatic at the time of diagnosis, with the 
RT- PCR test being performed due to surveillance protocols for 
being in contact with a SARS- CoV-2- positive subject (13 cases), 
for screening at the time of LT (8 cases) and for screening at 
hospital admission for cirrhosis complications (2 cases). On 
comparing the baseline characteristics of the two groups of symp-
tomatic and asymptomatic cases, no major significant differences 
emerged between the two populations (online supplemental table 
1). These 23 asymptomatic cases were excluded for the analysis 
and their outcome is reported in online supplemental figure 1. 
The remaining 113 subjects (113/136, 83.1%), representing the 
6.05% of the subjects on the WL, presented with symptomatic 
SARS- CoV-2 infection (COVID-19) and were analysed (figure 1 
and online supplemental figure 2).
Characteristics and clinical course of 113 patients with 
COVID-19
Thirty- three patients (29.2%) received homecare, and the 
remaining 80 patients (70.8%) required hospitalisation (figure 1), 
with 52 (65%) patients being treated in a general ward and 28 
(35%) in the ICU. Baseline patient characteristics are reported 
in table 1. The median age was 58.0 (IQR 53–63) and 61.9% 
were men. DC with or without hepatocellular carcinoma (HCC) 
(68.1%) and HCC on compensated cirrhosis (17.7%) were the 
main indications for LT.
Figure 1 Flowchart showing the selection of the study population and intermediate/final outcomes. LT, liver transplantation; WL, waiting list.
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Comorbidities
Forty- five (39.8%) patients had diabetes mellitus; 26 (23.2%) 
had arterial hypertension; 12 (10.7%) had renal function impair-
ment with serum creatinine of >2 mg/dL; and 5 (4.5%) had 
chronic obstructive lung diseases. Eighty- four (74.3%) patients 
had at least one comorbidity and 38 (33.6%) patients had two 
or more (table 1).
Clinical presentation and course
At diagnosis, the most common symptoms included fever (74 
patients, 65.5%), cough (64 patients, 56.6%) and dyspnoea 
(30 patients, 26.6%). Radiological imaging (CT scan or chest 
X- ray) showed typical ground- glass opacities in 61 cases (54%) 
(table 2), with bacterial pneumonia being superimposed in one- 
third of the cases (20/61=32.7%).
Overall, 56 (49.6%) patients required respiratory support 
during hospitalisation, with 13 requiring non- invasive ventila-
tion and 15 requiring,invasive mechanical ventilation. Forty- nine 
patients received specific anti- SARS- CoV-2 treatment based on 
local protocols. Twenty- nine patients (25.7%) were treated with 
low- molecular weight heparin. Two patients experienced pulmo-
nary thromboembolism; neither was on heparin prophylaxis.
Clinical features and outcomes in patients treated at home, in 
general wards and in the ICU
Baseline characteristics and disease course of patients with less 
severe symptoms who could be treated at home and of those 
with more severe symptoms requiring hospitalisation in general 
wards and in ICU are reported in online supplemental table 
2 and 3. Patients treated at home had lower Child- Pugh and 
Table 1 Baseline characteristics of the COVID-19 cases
Total (N=113)
Male, n (%) 70 (61.9)
Age at symptoms (years)
  Median (IQR) 58 (53–63)
Age class at symptoms (years), n(%)
  ≤50 23 (20.4)
  50–60 43 (38.1)
  >60 47 (41.6)
Location of patient at occurrence of symptoms, n(%)
  Home 75 (67)
  Hospital 35 (31.3)
  On arrival for LT 2 (1.8)
  Missing 1
Indication for LT, n (%)
  Decompensated cirrhosis with or without HCC* 77 (68.1)
  HCC 20 (17.7)
  Other† 16 (14.2)
Aetiology, n (%)
  Alcohol 30 (26.5)
  Alcohol+NASH 8 (7.1)
  Alcohol+HCV active or inactive 5 (4.4)
  AIH+PBC+PSC 17 (15)
  HBV 12 (10.6)
  HCV active or inactive 9 (8)
  NASH 8 (7.1)
  Other 24 (21.2)
Comorbidities,N(%)
  No 29 (25.7)
  Diabetes mellitus 45 (39.8)
  Arterial hypertension 26 (23)
  BMI>30 kg/m2 23 (20.4)
  Current or former tobacco smoker 18 (15.9)
  Kidney function impairment‡ 12 (10.6)
  Chronic obstructive lung disease 5 (4.4)
  Coronary artery disease 4 (3.5)
  Other 6 (5.3)
Number of comorbidities class, n (%)
  0 29 (25.7)
  1 46 (40.7)
  2 24 (21.2)
  ≥3 14 (12.4)
Drugs, n (%)
  No 63 (55.8)
  Beta blockers 37 (32.7)
  ACE inhibitors or angiotensin II receptor antagonists 7 (6.2)
  Beta blockers+ACE inhibitors 6 (5.3)
MELD score pre- COVID-19, n (%)
  Median (IQR) 16 (11–21)
  <15 42 (37.2)
  15–19 34 (30.1)
  ≥20 37 (32.7)
Child- Pugh score pre- COVID-19,§ n (%)
  Median (IQR) 8 (7–10)
  5–6 25 (23.6)
  7–9 42 (39.6)
  ≥10 39 (36.8)
  Missing 1
Continued
Total (N=113)
International Norm INR pre- COVID-19
  Median (IQR) 1.4 (1.2–1.8)
Bilirubin (mg/dL) pre- COVID-19
  Median (IQR) 2.7 (1–8)
Creatinine (mg/dL) pre- COVID-19
  Median (IQR) 0.9 (0.8–1.3)
Ascites pre- COVID-19,§ n (%)
  0=no 34 (32.7)
  1=only at ultrasound 17 (16.3)
  2=moderate 32 (30.8)
  3=severe or tense ascites 6 (5.8)
  4=refractory 15 (14.4)
  Missing 3
Hepatic encephalopathy pre- COVID-19,§ n (%)
  1=absent 81 (77.9)
  2=grades 1–2 21 (20.2)
  3=grades 3–4 2 (1.9)
  Missing 3
Pre- COVID-19 denotes most recent value before symptoms.
*72 of 77 patients without HCC and 5 of 77 with HCC.
†Re- LT for chronic rejection or hepatic artery thrombosis; autosomal dominant 
polycystic liver disease; neuroendocrine tumour; primary sclerosing cholangitis; 
surgical biliary complication.
‡P- creatinine >2 mg/dL
§6 patients without cirrhosis were excluded.
AIH, autoimmune hepatitis; BMI, Body Mass Index; HCC, hepatocellular carcinoma; 
INR, international normalised ratio; LT, liver transplant; NASH, non- alcoholic 
steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.
Table 1 Continued
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biochemical MELD scores, while age and number of comorbid-
ities were similar.
Wait-list mortality and predictive factors
Thirty- seven patients died (37/113, 32.7%) after a median of 
18 (IQR 10–30) days from diagnosis, the great majority (33/37, 
89.1%) with respiratory failure. The remaining four patients 
died of end- stage liver disease without respiratory failure after 
18, 67, 205 and 210 days from COVID-19 diagnosis with only 
two of them being SARS- CoV-2 negative. The cumulative inci-
dence of death and LT by competitive risk analysis is reported 
in online supplemental figure 3. On clinical presentation, 
the following five factors were significantly associated with 
mortality risk by univariable analysis: DC with or without HCC, 
dyspnoea, kidney function impairment with serum creatinine 
of >2 mg/dL, Lab- MELD class of 15–19 and Lab- MELD class 
of ≥20 (table 3). Estimated probability of survival stratified by 
main indication for LT (DC, HCC and other indications), Lab- 
MELD score on presentation (<15, 15–20 and >20), dyspnoea 
on presentation and kidney function impairment are shown 
in figure 2A–D. Three factors resulted significantly associated 
to mortality in multivariable analysis, namely, dyspnoea (HR 
3.89, 95% CI 2.02 to 7.51), MELD class of 15–19 (HR 5.46, 
95% CI 1.81 to 16.50) and MELD class of ≥20 (HR 5.24, 
95% CI 1.77 to 15.55). The Kaplan- Meier survival curves strat-
ified by MELD class of ≥15 or <15 and dyspnoea (present 
or absent) allowed a clear distinction between the individual 
mortality risks on clinical presentation (figure 3). Kaplan- Meier 
(KM) survival of the whole population and after stratification 
by place of management, defined as the place of highest inten-
sity of care during COVID-19 (at home, in general ward or in 
ICU), is provided in online supplemental figure 4. All patients 
managed at home survived, while the probability of survival at 
30 days was 80.8% (95% CI 67.2% to 89.2%) and 35.7% (95% 
CI 18.9% to 53.0%) for patients treated in the general ward 
and in the ICU, respectively, and this declined to 69.7% (95% 
CI 53.5% to 81.2%) and 24.5% (95% CI 10.6% to 41.5%) at 
90 days.
Table 2 Clinical presentation and course after COVID-19 symptoms
Total (N=113)
Symptoms at clinical diagnosis, n(%)
  Fever>37.2°C 74 (65.5)
  Cough 64 (56.6)
  Dyspnoea 30 (26.6)
  Fatigue 19 (16.8)
  Confusion 14 (12.4)
  Diarrhoea 13 (11.5)
  Muscle pain 9 (8)
  Thoracic pain 5 (4.4)
  Anosmia and dysgeusia 4 (3.5)
  Other 4 (3.5)
Chest X- ray or thorax CT scan, n(%)
  No 12 (10.7)
  Yes, normal 39 (34.8)
  Yes, ground- glass opacities 58 (51.8%)
  Yes, lobar infiltrates+ground- glass opacities 3 (2.7)
  Missing 1
Respiratory support, n(%)
  No 57 (50.4)
  O2 support 28 (24.8)
  Non- invasive ventilation 13 (11.5)
  Invasive mechanical ventilation 15 (13.3)
AD, n (%)
  No 75 (66.4)
  Yes 34 (30.1)
  Yes, unrelated to COVID-19 4 (3.5)
ACLF, n (%)
  No ACLF 93 (82.3)
  ACLF grade 1a 0 (0)
  ACLF grade 1b 2 (1.8)
  ACLF grade 2 3 (2.7)
  ACLF grade 3a 3 (2.7)
  Unrelated to COVID-19 1 of 3
  ACLF grade 3b 12 (10.6)
  Unrelated to COVID-19 2 of 12
CLIF- C ACLF score
  Median (IQR) 60.82 (11–42)
Renal replacement therapy, n (%) 9 (8)
Vasoactive drugs (norepinephrine), n (%) 16 (14.3)
Myocarditis, n (%) 3 (2.7)
Bilirubin (mg/dL): peak value
  Median (IQR) 3.2 (1.4–10.1)
INR: peak value
  Median (IQR) 1.5 (1.2–2)
Creatinine (mg/dL): peak value
  Median (IQR) 1.1 (0.8–1.6)
MELD score: peak value
  Median (IQR) 18 (13–25)
COVID-19 therapy, n (%)
  None 64 (56.6)
  Low- molecular weight heparin 29 (25.7)
  OH- chloroquine 16 (14.2
  Azythromicin 14 (12.4)
  High- dose steroids 7 (6.2)
  Lopinavir/ritonavir 5 (4.4)
  Tocilizumab 5 (4.4)
Continued
Total (N=113)
  Remdesevir 4 (3.5)
  Other 2 (1.8)
Outcome, n (%)
  Alive 75 (66.4%)
  Dead 37 (32.7%)
  Death after LT 1 (0.9%)
Time between symptoms and last follow- up (days)
  Median (IQR) 55 (27–183)
Cause of death, N (%)
  Respiratory failure 10 (27)
  Liver failure+respiratory failure 20 (54.1)
  Liver failure without respiratory failure 4 (10.8)
  Other causes+respiratory failure 3 (8.1)
Patients having received an LT, n (%) 26 (23)
Time between symptoms and LT (days), median (IQR) 78.5 (44–102)
ACLF, acute- on- chronic liver failure; AD, acute decompensation; CLIF- C, Chronic 
Liver Failure Consortium; LT, liver transplantation; MELD, Model for End- stage Liver 
Disease.
Table 2 Continued
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Impact of COVID-19 on liver function deterioration: AD and ACLF
A total of 38 patients (38/113=33.6%) presented or developed 
AD during COVID-19. Decompensation events included new 
or worsening ascites of 55.3% (21/38), hepatic encephalopathy 
of 57.9% (22/38), spontaneous bacterial peritonitis of 31.6% 
(12/38) and variceal haemorrhage of 13.2% (5/38). Twenty of 
these 38 patients with AD (55.2%) met the criteria for ACLF: 
grade 1b in 2, grade 2 in 3, grade 3a in 3 and grade 3b in 12, 
with mortality being significantly higher in patients with ACLF 
compared with no ACLF (85% vs 21.7%, p<0.001) (table 2).
Comparative analysis: ACLF induced by COVID-19 or by bacterial 
infection
Online supplemental table 4 shows the comparison between 
cirrhotic patients with COVID-19 listed for LT (n=106 of 113 
patients) and cirrhotic patients hospitalised for AD due to bacte-
rial infection (n=91) serving as the control group. The two 
cohorts were similar for gender distribution and MELD/Child- 
Pugh scores, whereas patients with COVID-19 were signifi-
cantly younger and their liver disease was less frequently caused 
by alcohol use disorders. The 30- day cumulative probability of 
overall mortality was similar, 24.8% (95% CI 17.6% to 34.2%) 
vs 28.5% (95% CI 20.2% to 39.3%, p=0.50), and did not 
vary across different MELD (<15, 15–19 and ≥20) and Child- 
Pugh classes, adjusted for possible confounders (online supple-
mental figure 5). ACLF incidence resulted lower in patients with 
COVID-19 (18.9% vs 30.8%), although mortality after devel-
oping ACLF was significantly higher for patients having ACLF 
triggered by COVID-19 (85% vs 53%), which is explained 
by the frequent occurrence of refractory respiratory failure in 
patients with COVID-19 and ACLF (18/20 vs 0/28).
Comparative analysis: first and second waves
Fifty- one patients developed COVID-19 between February and 
June 2020 (first wave), and 62 between July and November 
2020 (second wave) (online supplemental figure 6). Clinical 
presentation and course were similar between the two waves, 
the only difference being a twofold increase in the percentage of 
patients receiving heparin during the second wave. The 60- day 
mortality risk in the overall population was 35.3% (95% CI 
23.9% to 50.0%) vs 26.0% (95% CI 16.2% to 40.2%), and 
peaked to 43.9% (95% CI 30.4% to 60.3%) vs 41.7% (95% CI 
26.6% to 61.0%) in those requiring hospitalisation, with respi-
ratory failure being the major cause of death (table 4 and online 
supplemental figure 7).
Outcome of LT in patients with prior COVID-19
Twenty- six patients underwent an LT after a median interval of 
78.5 (IQR 44–102) days from diagnosis (table 2). Before being 
reactivated on the WL, all patients had to be asymptomatic and 
with a minimum of one negative RT- PCR rhinopharyngeal swab. 
An additional negative swab at the time of LT was required by all 
centres. Overall, the median ICU and hospital stay were 3 (IQR 
3–6) and 11 (IQR 8–19) days, respectively. Immunosuppression 
included a calcineurin inhibitor drug in all patients (24 tacrolimus 
Table 3 Results from univariate and multivariate analyses of baseline predictors of mortality, from Cox proportional hazard regression models
Variable
Univariable models Multivariable model
HR (95% CI) P value HR (95% CI) P value
Age (years)
  <50 1 ref
  50–64 1.028 (0.435 to 2.432) 0.95
  ≥65 1.827 (0.694 to 4.808) 0.22
Gender, male versus female 1.072 (0.551 to 2.084) 0.84
Indication for LT
  HCC 1 ref
  Decompensated cirrhosis without HCC 10.567 (1.444 to 77.327) 0.020
  Other 4.126 (0.429 to 39.682) 0.22
Aetiology
  HBV, HCV or other cirrhosis 1 ref
  Alcohol 1.354 (0.677 to 2.709) 0.39
  NASH 1.195 (0.348 to 4.107) 0.78
  Other non- cirrohsis 1.095 (0.251 to 4.776) 0.90
  Dyspnoea as presenting symptom 4.087 (2.139 to 7.808) <0.001 3.894 (2.018 to 7.514) <0.0001
  BMI≥30 vs BMI<30 0.860 (0.378 to 1.960) 0.72
  Diabetes mellitus (yes vs no) 1.426 (0.748 to 2.717) 0.28
  Kidney function impairment with p- creatinine>2 mg/dL 2.61 (1.142 to 5.972) 0.023
Number of comorbidities
  0 1 ref
  1 0.689 (0.298 to 1.595) 0.38
  2 0.831 (0.316 to 2.19) 0.71
  3+ 2.071 (0.813 to 5.271) 0.13
MELD class
  MELD<15 1 ref 1 ref
  MELD 15–19 5.267 (1.746 to 15.888) 0.003 5.463 (1.808 to 16.5016) 0.003
  MELD≥20 6.055 (2.048 to 17.906) 0.001 5.242 (1.768 to 15.545) 0.003
BMI, Body Mass Index; HCC, hepatocellular carcinoma; LT, liver transplantation; MELD, Model for End- stage Liver Disease; ref, reference.
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and 2 cyclosporine), with mycophenolate–mofetil being used in 
21 cases. Survival rate was 96% at a median follow- up of 118 
days (IQR 31–170), with a single patient dying from posterior 
reversible encephalopathy syndrome 82 days after LT.
DISCUSSION
This study reports on the first large cohort of patients who 
developed COVID-19 while listed for LT, and several novel 
findings regarding pretransplant and post- transplant outcomes 
were obtained, which are summarised as follows: LT candidates 
with symptomatic SARS- CoV-2 infection were at high risk of 
early death, particularly those with DC and Lab- MELD score of 
≥15. The mortality risk was dramatically increased in patients 
with a Lab- MELD score of ≥15 and with dyspnoea on presenta-
tion. COVID-19 was confirmed to be a potential trigger of AD 
and ACLF. Respiratory failure frequently resulted in candidates 
being ineligible for LT and was the most frequent cause of death. 
During the two waves of the pandemic, clinical presentation, 
course and mortality risk from COVID-19 did not significantly 
change. Finally, short- term survival after LT was 96%, and no 
cases of SARS- CoV-2 reinfection were observed to date.
In our analysis, liver transplant candidates with COVID-19 
showed a 30- day mortality probability which was similar to 
that observed in a control group of cirrhotic patients hospital-
ised for AD due to bacterial infection. The overall mortality 
rate was 32.7% (37/113) and reached 49.2% (31/63) in patients 
with DC and a Lab- MELD score of >15, which is triple the 
mortality risk observed in listed patients with comparable Lab- 
MELD scores without COVID-19.10 This indicates that liver 
Figure 2 Kaplan- Meier survival from the date of COVID-19 symptoms stratified by (A) indication for liver transplantation (DC without HCC, HCC, 
others); (B) MELD score categories; (C) dyspnoea on presentation; and (D) kidney function impairment. DC, decompensated cirrhosis; FI, function 
impairment; HCC, hepatocellular carcinoma; MELD, Model for End- stage Liver Disease.
Figure 3 Kaplan- Meier survival from the date of COVID-19 symptoms 
stratified by MELD score and dyspnoea on presentation. MELD, Model 
for End- stage Liver Disease.
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transplant candidates with DC should rigorously adopt all the 
usual measures to prevent SARS- CoV-2 infection and evidences 
the need for rapid implementation of reinforced vaccination 
programmes since the efficacy of standard vaccines will be likely 
lower than that reported in the registration studies. This is partic-
ularly relevant since the prevalence of COVID-19 in LT candi-
dates was 6.05%, which is double that observed in the general 
population of similar age,11 possibly due to higher susceptibility 
to SARS- CoV-2.
Despite the baseline Lab- MELD score being strongly asso-
ciated with mortality, COVID-19- related respiratory failure 
remained the predominant cause of death at 89.2% (33/37), 
remaining at 10.2% (4/37) due to liver- related complications, 
these results concurring with previous studies from Europe and 
the USA.12–17
Following multivariable analysis, two factors, namely, dyspnoea 
on presentation and baseline Lab- MELD score emerged as inde-
pendent predictors of mortality. Interestingly, patients listed for 
HCC had a much better outcome than those with DC, most 
likely because of associated lower Lab- MELD score at listing. 
The combination of Lab- MELD score of ≥15 and dyspnoea was 
associated with a negative prognosis, 60- day mortality risk of 
68.8% (50.1–85.2), while any other possible combination of 
these two simple baseline factors allowed an early stratifica-
tion of the mortality risk, and this may help clinicians in their 
decision- making. Despite what was observed in other patient 
cohorts, neither age nor comorbidities influenced the mortality 
risk, probably due to advanced age and increased comorbidities 
being exclusion criteria for WL.
COVID-19 led to a marked deterioration in liver function with 
high rates of AD (33.6%) and ACLF (17.6%) being observed. 
The occurrence of AD and ACLF in patients with COVID-19 
was associated with a mortality risk of 59% and 90%, respec-
tively, which compares unfavourably with the 44% and 65% 
observed by Marjot et al.16 This finding is probably due to the 
different prevalence of patients with advanced liver impairment 
between the two cohorts (Child- Pugh B/C 76% vs 48%). We 
also compared our cases of ACLF occurring after COVID-19 
with those observed in an appropriately balanced cohort of 91 
cirrhotic patients who were admitted for AD triggered by bacte-
rial infections. Notably, the mortality after developing ACLF 
was significantly higher for patients having ACLF triggered by 
COVID-19 (85% vs 53%), which is explained by the frequent 
occurrence of refractory respiratory failure in patients with 
COVID-19 and ACLF (18/20 vs 0/28).
A preliminary comparison between the two waves of the 
pandemic was possible. The 60- day mortality risk was 35.3% 
(95% CI 23.9% to 50.0%) during the first wave and did not 
significantly decline during the second wave (26%, 95% CI 
16.2% to 40.2%), with respiratory failure remaining the major 
cause of death. This suggests that the impact of newly estab-
lished therapies to control COVID-1918 19 is limited in patients 
with advanced liver disease. Patients with prior COVID-19 had 
favourable outcomes, with early survival of 96% (25/26) after 
receiving a liver transplant. Median ICU and total hospital stay 
were 3 (IQR 3–6) and 11 (IQR 8–19) days, which concur with 
what is observed in more recent series.20 To date, zero case of 
SARS- CoV-2 recurrence was observed after LT.
Mortality in the great majority of patients in this cohort 
was due to respiratory failure (33/37, 89.2%), with respira-
tory failure being a clear contraindication for proceeding 
with an LT. Thus, apprehension related to wait- listed patients 
not receiving a graft for organ unavailability due to a decline 
in organ donation, and competition for ICU beds seems 
unfounded. Although, it cannot be excluded that a minority of 
urgent patients, SARS- CoV-2 negative, may have died on the 
WL due to a decline in organ offers, being indirect victims of 
the COVID-19 pandemic.
Two main limitations are to be acknowledged for this study. 
First, focusing on symptomatic cases with confirmed positive 
SARS- CoV-2 PCR test despite test sensitivity below 80%, we 
found that some cases may have inadvertently been excluded. 
Second, the impact of the COVID-19 pandemic on access to LT 
could not be measured.
In conclusion, liver transplant candidates with a MELD score 
of >15 and presenting with COVID-19- associated dyspnoea are 
at high risk of respiratory failure and early death. Once patients 








Age at symptoms (years) 59 (53–63) 57 (52–64) 0.58
Site of highest intensity of care, n (%)
  Outpatient 10 (19.6) 23 (37.1) 0.093
  Ward 25 (49.0) 27 (43.6)
  ICU 16 (31.4) 12 (19.4)
MELD 17 (14–22) 15.5 (11–20) 0.30
Number of comorbidities 1 (0–2) 1 (1–2) 0.23
Symptoms, n (%)
  Fever>37.2°C 32 (62.7) 42 (67.7) 0.58
  Cough 25 (49) 39 (62.9) 0.14
  Dyspnoea 16 (31.4) 14 (22.6) 0.30
  Fatigue 5 (9.8) 14 (22.6) 0.071
  Confusion 6 (11.8) 8 (12.9) 0.86
  Diarrhoea 7 (13.7) 6 (9.7) 0.50
Ground- glass opacities, n (%) 34 (66.7) 27 (44.3) 0.018
Respiratory support 29 (56.9) 27 (43.6) 0.16
Acute decompensations, n (%)
  No 33 (64.7) 42 (67.7) 0.56
  Yes 15 (29.4) 19 (30.7)
  Yes, unrelated to COVID-19 3 (5.9) 1 (1.6)
ACLF, n (%)
  No 40 (78.4) 53 (85.5) 0.57
  Yes 9 (17.7) 8 (12.9)
  Yes, unrelated to COVID-19 2 (3.9) 1 (1.6)
COVID-19 therapy, n (%)
  High- dose steroid 2 (3.9) 5 (8.1) 0.45
  Low- molecular weight 
heparin
8 (15.7) 21 (33.9) 0.028
60- day mortality probability, % 
(95% CI): overall
35.3 (23.9 to 
50.0)
25.9 (16.2 to 
39.9)
0.23
60- day mortality probability, 
% (95% CI): in hospitalised 
patients
43.9 (30.0 to 
60.3)
41.2 (26.5 to 
61.0)
0.72
Cause of death, (%)
  Respiratory failure 8 (36.4) 2 (13.3) 0.31
  Liver failure+respiratory 
failure
10 (45.5) 10 (66.7)
  Liver failure without 
respiratory failure
3 (13.6) 1 (6.7)
  Other causes+respiratory 
failure
1 (4.6) 2 (13.3)
ACLF, acute- on- chronic liver failure; MELD, Model for End- stage Liver Disease.
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Uncited Box 1 Centers participating to the ELITA/ELTR Covid-19 project in liver transplantation including all collaborators at 
each site
1. Hepatology and Gastroenterology Unit, ASST GOM Niguarda, Milan, Italy: Luca S Belli, Giovanni Perricone, Raffaella Viganò and Chiara 
Mazzarelli, General Surgery and Abdominal Transplantation Unit, ASST GOM Niguarda, and School of Medicine and Surgery, University 
of Milano- Bicocca, Milan, Italy: Luciano G De Carlis, Andrea Lauterio and Alessandro Giacomoni. Department of Infectious Diseases Unit, 
ASST GOM Niguarda, Milan, Italy. Marco Merli, Giovanni Travi and Massimo Puoti.
2. Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy: Federica 
Invernizzi, Francesca Donato nd Pietro Lampertico.
3. Papa Giovanni XXIII Hospital, Bergamo Italy. Department of Gastroenterology, Hepatology and Transplantation: Luisa Pasulo and 
Stefano Fagiuoli. Department of Surgery: Marco Zambelli, Michela Guizzetti and Michele Colledan.
4. Internal Medicine Unit of Treatment of Severe Organ Failure, IRCCS Azienda Ospedaliero- Universitaria di Bologna Policlinico di 
Sant'Orsola. Maria Cristina Morelli and Giovanni Vitale.
5. Gastro- hepatology Unit: Silvia Martini and Antonio Ottobrelli. Liver Transplantation Center: Damiano Patrono and Renato Romagnoli. 
Azienda Ospedaliera Universitaria, Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy.
6. Department of Surgery, University of Modena E Reggio Emilia, Policlinico Di Modena, Modena, Italy: Fabrizio Di Benedetto.
7. Ospedale Cisanello, UO Trapiantologia Epatica Universitaria Azienda Ospedaliera, Pisa, Italy: Paolo De Simone, Paola Carrai and 
Petruccelli Stefania.
8. Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova Paolo Angeli, Salvatore Piano, Simone 
Incicco and Nicola Zen.
9. Hepato- bilio- pancreatic Surgery and Transplantation Department, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg: 
Francoise Faitot and Baptiste Michard.
10. Centre Hepato- Biliaire, AP- HP Hôpital Paul Brousse Hospital, Paris- Sud Saclay University, Villejuif, France: Ilias Kounis, Audrey Coilly, 
Saliba Faouzi, Rene Adam, Vincent Karam and Didier Samuel.
11. Hôpital Henri Mondor, Service d’Hepatologie, Créteil, France: Christophe Duvoux and Norbert Ngongang.
12. Department of Hepatogastroenterology, Hepatology and Liver Transplantation Unit: Sylvie Radenne, Domitille Poinsot and Celine 
Guichon; Department of Digestive Surgery and Liver Transplantation: Mickael Lesurtel; Croix- Rousse University Hospital, Hospices Civils de 
Lyon, University of Lyon I, Lyon, France.
13. Hepatogastroenterology Unit, Hôpital Trousseau, CHRU de Tours, Tours, France: Laure Elkrief.
14. Hôpital Du Kremlin Bicêtre, Sce De Chirurgie Pédiatrique, Le Kremlin Bicêtre, France: Emmanuel Gonzales.
15. The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK: Darius Mirza, Thamara Perera and Angus Hann.
16. University of Edinburgh Royal Infirmary, Liver Transplantation Unit, Edinburgh, UK. Gabriel Oniscu and Chris Johnston.
17. Department of HPB and Transplant Surgery, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, UK: Derek Manaz.
18. Hospital Clinic de Barcelona, General and Digestive Surgery Department, IDIBAPS, CIBERehd, Barcelona, Spain: Costantino 
Fondevila, Jordi Colmeneroas and David Toapanta.
19. Hospital Universitari Vall D'Hebron, Liver Unit and HBP Surgery and Transplants Department, Barcelona, Spain: Lluis Castells and 
Ernest Hidalgo.
20. Hospital Gregorio Maranon, Liver Transplant Unit, Madrid, Spain: Magdalena Salcedo Plaza and Fernando Diaz- Fontenla.
21. Liver Transplant Unit, Hospital Virgen del Rocio, Seville, Spain: Jose Maria Alamo.
22. Hospital Universitario Virgen De La Nieves, Servicio de Cirurgia General, Granada, Spain. Esther Brea Gomes.
23. Cirurgia HPB y Transplante Hepatico, Hospital Universitario de Badajoz, Spain: Gerardo Blancoa and Alberto Marcacuzco.
24. Hospital General Universitario De Alicante, Unidad Transplantes Hepatico, Alicante, Spain: Gonzalo Rodriguez and Sonia Pascual.
25. Hospital Universitario 12 de Octubre, HBP And Transplant Unit, General Surgery, Madrid, Spain: Carmelo Loinaz.
26. Division of Transplantation, Department of General Surgery, Medical University of Vienna, Austria: Gabriela Berlakovich, Dagmar 
Kollmann and Georg Györi.
27. Universitaire Ziekenhuizen Leuven, Abdominal Transplant Surgery, Leuven, Belgium: Jacques Pirenne and Natalie Vandende.
28. Hopital Erasme Universite Libre De Bruxelles, Department of Abdominal Surgery, Brussels, Belgium: Valerio Lucidi.
29. Erasmus MC, Transplant Institute, University Medical Center Rotterdam, Department of Surgery, Division of Hepatobiliary Surgery 
and Liver Transplantation, Rotterdam, The Netherlands. Wojciech G. Polak; Department of Gastroenterology and Hepatology: Caroline den 
Hoed.
30. Department of Abdominal Surgery and Transplantation, CHU Liege, University of Liege, Belgium: Olivier Detry.
31. Department of Surgery: Christian Toso; Divisions of Transplantation and of Gastroenterology and Hepatology: Giulia Magini and 
Nicolas Goossens; Geneva University Hospitals, Geneva, Switzerland.
32. Huddinge Hospital, Department of Transplantation Surgery, Huddinge, Sweden: Bo Goran Ericzon and Carl Jorns.
33. Digestive Diseases and Liver Transplantation Center from Fundeni Clinical Institute, Bucharest, Romania: Liana Gheorghe, Speranta 
Iacob and Irinel Popescu.
34. Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland: Joanna Raszeja- Wyszomirska 
and Krzysztof Zieniewicz.
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recover from COVID-19, LT is a safe option with no evidence of 
SARS- CoV-2 recurrence.
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